Current and future directions for treating hepatitis B virus infection

Table 1 Treatment efficacy at 24 wk after the end of peginterferon treatment in hepatitis B e antigen-positive chronic hepatitis B

Ref.	No. of patients	Formula of therapy	Seroconversion from HBeAg to anti-HBe (%)	Suppression of HBV DNA (%)	Normalization of ALT (%)	HBsAg loss (n)
Cooksley et al[27]	51	IFNα-2a 4.5 MIU three times weekly for 24 wk	25	25a	26	0
	49	Peg-IFNα-2a 90 μg weekly for 24 wk	37	43a	43	0
	46	Peg-IFNα-2a 180 μg weekly for 24 wk	35	39a	35	0
	48	Peg-IFNα-2a 270 μg weekly for 24 wk	27	27a	31	0
Lau et al[28]	214	Peg-IFNα-2a 180 μg weekly plus placebo for 48 wk	32	32b	41	8
	271	Peg-IFNα-2a 180 μg weekly plus LAM 100 mg daily for 48 wk	27	34b	39	8
	272	LAM 100 mg/d for 48 wk	19	22b	28	0
Chan et al[29]	50	Peg-IFNα-2b 1.5 μg/kg weekly for 32 wk plus LAM 100 mg daily for 52 wk	36	36a	50	1
	50	LAM 100 mg daily for 52 wk	14	14a	30	0
Liaw et al[30]	140	Peg-IFNα-2a 90 μg weekly for 24 wk	14	21c	30	1
	136	Peg-IFN α-2a 180 μg weekly for 24 wk	22	21c	30	0
	136	Peg-IFNα-2a 90 μg weekly for 48 wk	25	32c	43	3
	136	Peg-IFNα-2a 180 μg weekly for 48 wk	36	42c	52	3

a < 500000 copies/mL; b < 100000 copies/mL; c < 20000 copies/mL. LAM: Lamivudine; Peg-IFN: Peginterferon; HBV: Hepatitis B virus; HBeAg: Hepatitis B e antigen; HBsAg: Hepatitis B surface antigen; Anti-HBe: Antibody to HBe antigen; ALT: Alanine aminotransferase.